Medspa Consolidation in 2026: What Owners Need to Know

14 minutes ago

4 min read

Private equity hasn't taken over the medspa industry. But it is reshaping the competitive landscape faster than most independent owners realize, and that changes the decisions in front of you, whether you ever plan to sell or not.

Here is where things actually stand in 2026, what buyers are looking for, and the moves worth making regardless of which path you choose.

What's Actually Happening in Medspa M&A Right Now

Most of the headlines overstate it. More than 90% of medical spas in the United States remain independently owned, a figure the American Med Spa Association has reported consistently since 2022. Private equity firms own roughly 3% of the market, also unchanged from AmSpa's earlier research. This is not a gold rush.

What is true: deal activity has been steady and is expected to continue through 2026 and 2027. 2025 was described by industry M&A advisors as a year of add-on acquisitions rather than headline mega-deals. PE-backed platforms and management services organizations (MSOs) kept buying, particularly in high-growth states like Florida, Texas, and California. Several large PE-backed platforms built over the past few years are now approaching the point where their original investors look to resell or recapitalize, which is expected to drive more platform-level activity in 2026 and 2027.

Market-size estimates vary widely between research firms, anywhere from roughly $18 billion to $22 billion for different scopes in 2024, with projections ranging as high as $49 billion by 2030. Treat any single number with caution. What matters for your business isn't the size of the market, it's what's happening in your own metro area.

What Private Equity Buyers Actually Want

If you're ever approached, or just curious what makes a practice attractive, buyers are consistent about what they're looking for:

Multiple locations. Groups with three to eight or more sites draw the most competitive interest. A single location, even a highly profitable one, is a much harder sell to a platform looking to scale.
Centralized, documented systems. Standardized operating procedures across locations, not tribal knowledge held by a manager or injector.
Clean, defensible financials. Buyers want EBITDA they can verify, not EBITDA you explain. Mixed personal and business expenses, inconsistent bookkeeping, or revenue concentrated in one provider's personal following are all red flags.
Documented medical oversight. Clear, compliant structures for how licensed physicians supervise clinical decisions. Given how much regulatory attention medspas have drawn in 2026, this has become a bigger diligence item than it was a few years ago, not a smaller one.

If you're thinking about what your practice is actually worth and what drives that number, we covered the valuation mechanics in detail in Medspa Valuation 2026: What's Your Practice Worth?.

Why This Matters Even If You Never Plan to Sell

Here's the part independent owners underestimate: consolidation changes your competitive environment even if you stay out of it entirely.

PE-backed platforms typically bring centralized marketing budgets, negotiated supplier pricing on injectables and devices, and standardized patient-acquisition systems. A well-capitalized competitor with three locations and a shared marketing team can outspend and out-system a single independent practice, even one with better clinical outcomes and a more loyal following.

That doesn't mean you need to sell or merge to compete. It means the operational bar in your market is rising, and running on instinct and a great reputation alone gets harder every year that consolidation continues.

Before You Entertain Any Offer: Questions to Ask First

If a buyer, broker, or MSO does approach you, slow down before you get excited about a number. A few questions matter more than the headline multiple:

What's the actual deal structure? A high purchase price with a large rollover equity component or a long earnout means most of your payday depends on the new owner's performance, not just your own. Understand exactly how much cash you get at close versus later, and under what conditions.
Who owns clinical decision-making after the deal? Corporate practice of medicine laws vary significantly by state, and a deal structure that looks fine in one state can be a compliance problem in another. This is not something to take the buyer's word on.
What happens to your staff, your name, and your patients' records? Get specific commitments in writing, not verbal assurances made during the courtship phase.
Have you had your own attorney and CPA review it, independent of anyone the buyer recommends? Buyers routinely offer to "make this easy" by recommending counsel. Don't use it.

None of this means a sale is a bad idea for the right owner at the right time. It means a good deal survives scrutiny, and a bad one depends on you not asking these questions.

Build Optionality: Four Moves to Make Regardless of Your Plans

Whether you want to sell in two years, grow to a second location, or simply stay independent and competitive, the same groundwork pays off:

Separate personal and business finances completely, and keep monthly financials clean enough that a stranger could understand them in an hour.
Document your systems. We walked through how to build this kind of operational backbone in Building Scalable Systems for Your Medspa. It matters whether you're scaling or just want the business to run without you for two weeks.
Formalize your medical oversight structure in writing, and keep it current as your state's rules evolve.
Diversify who drives revenue. A practice that lives or dies with one injector's personal following is fragile, whether you're being valued by a buyer or just trying to take a vacation.

The Takeaway

Consolidation in medspas is real, but it's not inevitable, and it's not happening to you whether you like it or not. Most of the industry is still independent, and that's likely to remain true for years. What's changed is the competitive bar: the practices thinking like a business, with clean numbers, documented systems, and airtight medical oversight, are the ones with real choices in 2026, whether that choice is to sell, grow, or simply keep winning as an independent. Start with the fundamentals, and the rest of the decision gets a lot easier.